Introduction: Mild cognitive impairment in adults with vascular risk factors has various trajectories of disease progression, including to dementia, improvement in cognitive functions, or stabilization. The aim of the study was to evaluate the trajectory of mild cognitive impairment in adult patients with vascular risk factors after 36 months.

Materials and Methods: A longitudinal observational study was conducted from September 2019 to November 2022 and included 194 outpatients. During the study, 51 patients were excluded for various reasons: desire to early terminate participation in the study (n=18), inability to comply with the study protocol (n=20), death (n=3). Neuropsychological testing was performed at baseline and at the end of the study using the Montreal Cognitive Assessment (MoCA) to determine the MoCA-total and MoCA memory index. During the study, patients received stable therapy aimed at correcting modifiable vascular risk factors.

Results and Discussion: 143 patients (55.2% women, mean age 57.7±6.6 years) completed all study procedures. Baseline MoCA-total was a median of 22.2 (IQR 18.3-24.4) points, MoCA memory index − the median of 9.2 (IQR 6.7-12.9) points. After 36 months, 19.6% patients showed progression of mild cognitive impairment to dementia, the median MoCA memory index was 4.6 (IQR 3.1-5.7) points, 43.3% patients showed worsening of cognitive impairment, the median MoCA memory index was 8.2 (IQR 5.5-12.1) points, 37.1% patients had a stable state of cognitive functions, the median MoCA memory index was 9.5 (IQR 7.0-13.8) points.

Conclusions: Therapies aimed at correcting vascular risk factors are insufficient to maintain cognitive health, and additional therapeutic strategies are needed to specifically target the cognitive status of adult patients.

Victoria Fateeva, PhD, Assistant, Department of Nervous Diseases, Institute of Professional Education. In 2020, she defended her dissertation for the degree of candidate of medical sciences on the topic "The ratio of markers of endothelial dysfunction and anxiety-depressive spectrum disorders in middle-aged patients". Main areas of scientific research: The study of cognitive impairment of varying severity, endothelial function in norm and in chronic somatic diseases. She is proficient in methods that meet the standards of international research and are necessary for the successful implementation of the proposed project. Her studies have been carried out on aspects of biomarker diagnostics, prognosis and controlled therapy of cognitive impairment in cerebrovascular diseases, assessment of pathogenetically significant biomarkers of endothelial dysfunction and endothelial inflammation, participation in the development of an optimal biomarker panel for the purpose of a personalized approach to managing patients with cerebrovascular insufficiency. Has the skills to determine the concentration of markers of endothelial dysfunction and endothelial inflammation in the blood. Has experience working with the necessary equipment for conducting experiments, collecting and analyzing data and the appropriate software. She coordinates the scientific work of students, residents on the basis of the Sechenov University. Results of scientific activity of her is published in more than 50 publications, including chapters of the National Guidelines "Neurorehabilitation", "Association between peripheral blood inflammatory markers, endothelial dysfunction markers, and depression". London: IntechOpen; 2019, and one patent for invention. Hirsch index - 7. Hirsch index Scopus – 4.